

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TISSEEL safely and effectively. See full prescribing information for TISSEEL.

### TISSEEL [Fibrin Sealant]

#### For Topical Use Only

Frozen solution and lyophilized powder for solution for topical application

Initial U.S. Approval: 1998

#### RECENT MAJOR CHANGES

Indications and Usage (1) xx/20xx

#### INDICATIONS AND USAGE

**Hemostasis:** TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in patients undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients.(1.1)

**Sealing:** TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies (1.2)

#### DOSAGE AND ADMINISTRATION

##### For Topical Use Only. Do Not Inject (2)

- Apply TISSEEL as a thin layer by dripping or spraying using cannula or spray set (2.3, 5.2)
- Ensure that the amount of TISSEEL to be applied is sufficient to entirely cover the intended application area (2.3)

#### DOSAGE FORMS AND STRENGTHS

TISSEEL Kit (Freeze-Dried) is supplied as 2 mL, 4 mL and 10 mL (total volume) pack sizes with and without the DUPLOJECT System (3)

TISSEEL Pre-filled Syringe (Frozen) is supplied as 2 mL, 4 mL and 10 mL (total volume) pack sizes with the DUO Set (3)

#### CONTRAINDICATIONS

- Do not inject directly into the circulatory system or into highly vascularized tissue (4.1, 5.3)
- Do not use in individuals with a known hypersensitivity to aprotinin (4.2, 5.1, 6)
- Do not use for the treatment of severe or brisk arterial or venous bleeding (4.3)

#### WARNINGS AND PRECAUTIONS

- TISSEEL contains aprotinin, a protein known to be associated with anaphylactic reactions (4.2, 5.1, 6)
- Air or gas embolism has occurred when fibrin sealant was administered using pressurized gas. This may occur if a spray device is used at higher than recommended pressures and in close proximity to the surface of the tissue (5.2)
- TISSEEL is denatured when exposing to solutions containing alcohol, iodine or heavy metals.(5.2)
- Apply only as a thin layer as excess clot thickness may negatively interfere with wound healing (2, 5.2)
- Exercise caution to minimize the risk of intravascular application when using TISSEEL in surgery (4.1, 5.3, 6.2)
- Safety has not been evaluated in neurosurgical procedures (5.4)
- TISSEEL is made from pooled human plasma which may contain infectious agents (5.5)

#### ADVERSE REACTIONS

Hypersensitivity or allergic/anaphylactoid reactions have occurred (6)

To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

#### DRUG INTERACTIONS

Oxidized cellulose-containing preparations may reduce the efficacy of TISSEEL and should not be used as carrier materials (7)

#### USE IN SPECIFIC POPULATIONS

Pregnancy: No human or animal data. Use only if clearly needed (8.1)

See 17 for PATIENT COUNSELING INFORMATION

Revised: xx/20xx

## FULL PRESCRIBING INFORMATION: CONTENTS \*

### 1 INDICATIONS AND USAGE

1.1 Hemostasis

1.2 Sealing

### 2 DOSAGE AND ADMINISTRATION

2.1 Preparation of TISSEEL Kit (Freeze-Dried)

2.2 Preparation of TISSEEL Pre-Filled Syringe (Frozen)

2.3 Method of Application

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

4.1 Intravascular Application

4.2 Aprotinin Hypersensitivity

4.3 Severe or Brisk Bleeding

### 5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity/Allergic/Anaphylactic Reactions

5.2 Application Precautions

5.3 Use in Surgery

5.4 Use in Neurosurgical Procedures

5.5 Infection Risk from Human Plasma

### 6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Post Marketing Experience

### 7 DRUG INTERACTIONS

### 8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

### 11 DESCRIPTION

11.1 Viral Clearance

### 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

### 13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

14.1 Vascular Surgery

14.2 Cardiac Surgery

14.3 Cardiac Reoperations

14.4 Splenectomy

14.5 Colostomy Closure

### 16 HOW SUPPLIED/STORAGE AND HANDLING

### 17 PATIENT COUNSELING INFORMATION

\* Sections or subsections omitted from the full prescribing information are not listed.

1 **FULL PRESCRIBING INFORMATION**

2  
3 **1 INDICATIONS AND USAGE**

4 **1.1 Hemostasis:** TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in patients undergoing surgery when control of bleeding by  
5 conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients.

6  
7 **1.2 Sealing:** TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from  
8 colonic anastomoses following the reversal of temporary colostomies.

9  
10 **2 DOSAGE AND ADMINISTRATION**

11 **FOR TOPICAL USE ONLY – DO NOT INJECT**

12 Vials and pre-filled syringes are for single use only. Discard any unused product.

13  
14 **2.1 Preparation of TISSEEL Kit (Freeze-Dried)**

15  
16 **DO NOT EXPOSE TO TEMPERATURES ABOVE 37°C**

17 **DO NOT MICROWAVE**

18 **DO NOT REFRIGERATE OR FREEZE AFTER RECONSTITUTION**

19  
20 **Do not use iodine or heavy metal containing preparations such as betadine for disinfection of vial stoppers.**

21 **Allow alcohol-based disinfectants to evaporate before puncturing stopper.**

22  
23 Use separate syringes and transfer devices for reconstituting Sealer Protein and Thrombin solutions and for application to prevent clotting.

24 The product must be used within 4 hours after reconstitution.

25  
26 Freeze-dried Sealer Protein Concentrate and Thrombin are reconstituted in Fibrinolysis Inhibitor Solution and Calcium Chloride Solution, respectively.

27 The Sealer Protein Solution and Thrombin Solution are then combined using the DUPLOJECT Preparation and Application System, or an equivalent  
28 delivery device cleared by FDA for use with TISSEEL, to form the Fibrin Sealant.

29  
30 Prewarming TISSEEL Kit with FIBRINOTHERM

31 See FIBRINOTHERM manual for complete operating instructions. If a FIBRINOTHERM device is not available, contact Baxter (1-800-423-2090) for  
32 assistance.

- 33 1. Place all four vials from the TISSEEL Kit into the prewarmed wells of the FIBRINOTHERM, using the appropriately sized adapter ring(s), and  
34 allow the vials to warm for up to 5 minutes (room temperature product will take less time).

35 Preparation of Sealer Protein Solution with FIBRINOTHERM

- 36 1. Remove the caps from the Sealer Protein Concentrate and the Fibrinolysis Inhibitor Solution vials.  
37 2. Transfer the Fibrinolysis Inhibitor Solution into the vial containing the freeze-dried Sealer Protein Concentrate using the sterile reconstitution  
38 components (see directions provided with the device system for specific reconstitution instructions). Gently swirl the vial to ensure that the  
39 product is completely soaked.  
40 3. Place the vial into the largest opening of the FIBRINOTHERM device with the appropriate adaptor. Switch on the stirrer and allow the vial  
41 contents to stir until all Sealer Protein Concentrate is dissolved. Reconstitution is complete when no undissolved particles are visible.

42 **Notes:**

- 43 - If the Sealer Protein Concentrate has not fully dissolved within 20 minutes discard the vial and prepare a fresh kit.  
44 - Keep the Sealer Protein Solution at 37°C without stirring. Stir shortly before drawing up the solution to ensure homogeneity.

45  
46 Preparation of Thrombin Solution with FIBRINOTHERM

47 To reconstitute the Thrombin (Human) with the Calcium Chloride Solution; follow steps 1-3 under **Preparation of Sealer Protein with FIBRINOTHERM**  
48 utilizing the Thrombin and Calcium Chloride vials.

49  
50 Transferring to the Sterile Field

51 For transfer of the Sealer Protein and Thrombin Solutions to the sterile field, the circulating nurse should disinfect the tops of the vials with a germicidal  
52 solution and allow to dry. The scrub nurse should withdraw the sterile solutions while the circulating nurse holds the non-sterile vials. The solutions  
53 should be withdrawn slowly by firm constant aspiration to reduce the risk of large air bubbles.

54  
55 **2.2 Preparation of TISSEEL Pre-Filled Syringe (Frozen)**

56  
57 **DO NOT EXPOSE TO TEMPERATURES ABOVE 37°C**

58 **DO NOT MICROWAVE**

59 **DO NOT REFRIGERATE OR RE-FREEZE**

60  
61 Do not use TISSEEL (frozen) until it is completely thawed and warmed (liquid consistency) to 33-37°C.

62 Do not remove the protective syringe cap until use.

63  
64 Sterile Water Bath (Quick Thawing): Transfer inner pouch to the sterile field, remove pre-filled syringe from inner pouch and place directly into sterile  
65 water bath ensuring the syringe is completely immersed in the water. Maintain the product at 33-37°C until use. If the package is opened or warmed to  
66 33-37°C, it must be used within 4 hours.

67  
68 Non-Sterile Water Bath: Maintain the pre-filled syringe in pouches and place into a water bath outside the sterile field ensuring the pouches remain  
69 submerged. Remove from the water bath after thawing and warming, dry the external pouch and transfer inner pouch with pre-filled syringe onto the  
70 sterile field. Maintain the product at 33-37°C until use. If the package is opened or warmed to 33-37°C, it must be used within 4 hours.

72 **Incubator:** Maintain the pre-filled syringe in pouches and place into an incubator. Remove from the incubator after thawing and warming. Transfer inner  
 73 pouch with pre-filled syringe onto the sterile field. Maintain the product at 33-37°C until use. If the package is opened or warmed to 33-37°C, it must be  
 74 used within 4 hours.

75  
 76 **Table 1: Approximate Water Bath or Incubator Thawing and Warming Times**

Pack Size	Sterile Water Bath (Pouches Removed) 33 - 37°C	Non-Sterile Water Bath (In Pouches) 33 - 37°C	Incubator (In Pouches) 33 - 37°C
2 mL	5 minutes	30 minutes	40 minutes
4 mL	5 minutes	40 minutes	85 minutes
10 mL	12 minutes	80 minutes	105 minutes

77  
 78 **Room Temperature Thawing:** Unopened pouches may be stored for up to 48 hours at room temperature (15-25°C). Before use, warm the product to 33-  
 79 37°C and apply immediately. The total thawing and warming time cannot exceed 48 hours.

80  
 81 **Table 2: Approximate Room Temperature Thawing Times**

Pack Size	Room Temperature (In Pouches) 15 – 25°C
2 mL	60 minutes
4 mL	110 minutes
10 mL	160 minutes

82  
 83 **Table 3: Approximate Water Bath or Incubator Warming Times for Thawed Product**

Pack Size	Sterile Water Bath (Pouches Removed) 33 – 37°C	Non-Sterile Water Bath (In Pouches) 33 – 37°C	Incubator (In Pouches) 33 – 37°C
2 mL	2 minutes	16 minutes	20 minutes
4 mL	2 minutes	21 minutes	43 minutes
10 mL	6 minutes	43 minutes	52 minutes

84  
 85  
 86 **2.3 Method of Application**

87 Dry the site of application as much as possible.

88  
 89 Apply TISSEEL as a thin layer by dripping or spraying using a cannula or spray set. The treating physician will determine the amount of TISSEEL to be  
 90 applied based on the surface to be covered. Ensure that the amount applied is sufficient to entirely cover the intended application area. The  
 91 approximate surface areas covered by each package size of TISSEEL are listed in Table 4:

92  
 93 **Table 4: Surface Area Coverage**

Required package size of TISSEEL	Maximum coverage using spray	Maximum coverage using cannula
2 mL	100 cm <sup>2</sup>	8 cm <sup>2</sup>
4 mL	200 cm <sup>2</sup>	16 cm <sup>2</sup>
10 mL	500 cm <sup>2</sup>	40 cm <sup>2</sup>

94  
 95 Avoid application beyond the intended area. Allow at least 2 minutes after application to achieve sufficient polymerization. If repeat application is  
 96 needed, dry the site as much as possible before reapplying. Reapply after removing residues from the prior application or before polymerization takes  
 97 place since TISSEEL may not adhere firmly to a polymerized layer.

98  
 99 In cases where very small volumes (1-2 drops) are required, expel and discard the first several drops from the application cannula immediately before  
 100 application to ensure administration of adequately mixed TISSEEL.

101  
 102 Exercise caution when applying TISSEEL using pressurized gas [see *Warnings and Precautions (5.2)*].

103  
 104 The product name, batch number and patient information should be recorded for traceability purposes.

105  
 106 **TISSEEL Kit (Freeze-Dried)**

107 Apply TISSEEL using the DUPLOJECT Fibrin Sealant Preparation and Application System or an equivalent delivery device (including open and  
 108 minimally invasive spray devices) cleared by FDA for use with TISSEEL. Specific instructions for the use of TISSEEL in conjunction with each cleared  
 109 delivery device are provided with the device.

110  
 111 **TISSEEL Pre-filled Syringe (Frozen)**

112 Apply pre-filled TISSEEL using the DUO Set accessory devices provided with the product or an equivalent delivery device (including open and minimally  
 113 invasive spray devices) cleared by FDA for use with TISSEEL.


114 DUO Set Instructions (see Figure 1 below):

- 115 1. Insert plunger into syringe barrel.
- 116 2. Firmly connect the two syringe nozzles to the joining piece (Y connector) and secure it by fastening the tether strap to the syringe.
- 117 3. Fit an application cannula to the joining piece. Apply by depressing plunger.

118 Note: Interruption of TISSEEL application causes clogging in the cannula. Replace the cannula immediately prior to resuming application. If  
 119 the opening of the joining piece (Y connector) facing the cannula is clogged, use the spare joining piece provided in the package.

121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195

**Figure 1  
DUO SET**



### 3 DOSAGE FORMS AND STRENGTHS

TISSEEL Kit (Freeze-Dried) is supplied as 2 mL, 4 mL and 10 mL (total volume) pack sizes with and without the DUPLOJECT System. TISSEEL Pre-Filled Syringe (Frozen) is supplied as 2 mL, 4 mL and 10 mL (total volume) pack sizes with the DUO Set.

### 4 CONTRAINDICATIONS

#### 4.1 Intravascular Application

**Do not inject TISSEEL directly into the circulatory system or into highly vascularized tissue. Intravascular application of TISSEEL can lead to intravascular coagulation, may result in life-threatening thromboembolic events, and may increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients** (see *Warnings and Precautions (5.3)* and *Adverse Reactions (6.2)*).

#### 4.2 Aprotinin Hypersensitivity

Do not use TISSEEL in individuals with a known hypersensitivity to aprotinin (see *Warnings and Precautions (5.1)* and *Adverse Reactions (6)*).

#### 4.3 Severe or Brisk Bleeding

Do not use TISSEEL for treatment of severe or brisk arterial or venous bleeding. In these situations, TISSEEL will be washed away in the flow of blood before hemostasis can be attained.

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Hypersensitivity/Allergic/Anaphylactic Reactions

Hypersensitivity or allergic/anaphylactoid reactions may occur with the use of TISSEEL. Cases (<1/10,000) have been reported in post marketing experience with Baxter's fibrin sealant (see *Adverse Reactions (6.2)*). In specific cases, these reactions have progressed to severe anaphylaxis. Such reactions may especially be seen if TISSEEL is applied repeatedly over time or in the same setting, or if systemic aprotinin has been administered previously. Even if the first treatment was well tolerated, this may not exclude the occurrence of an allergic reaction after a subsequent administration of TISSEEL or systemic aprotinin. Observed symptoms of allergic anaphylactic reactions to TISSEEL have included: bradycardia, tachycardia, hypotension, flushing, bronchospasm, wheezing, dyspnea, nausea, urticaria, angioedema, pruritus, erythema and paresthesia. Such reactions may also occur in patients receiving TISSEEL for the first time.

Aprotinin is included in TISSEEL for its antifibrinolytic properties. Aprotinin, a protein, is known to be associated with anaphylactic reactions. Even in the case of strict local application of aprotinin, there is a risk of anaphylactic reactions to aprotinin, particularly in the case of previous exposure (see *Contraindications (4.2)*). TISSEEL does not contain any substances of bovine origin.

Discontinue administration of TISSEEL in the event of hypersensitivity reactions. Mild reactions can be managed with antihistamines. Severe hypotensive reactions require immediate intervention using current principles of shock therapy. Remove remaining product from the application site.

#### 5.2 Application Precautions

Air or gas embolism has occurred when fibrin sealant was administered using pressurized gas. This may occur if a spray device is used at higher than recommended pressures and in close proximity to the tissue surface.

When applying TISSEEL using a spray device, be sure to use the pressure within the pressure range recommended by the spray device manufacturer. In the absence of a specific recommendation avoid using pressure above 20-25 psi. Do not spray closer than the distance recommended by the spray device manufacturer. In the absence of a specific recommendation avoid spraying closer than 10-15 cm from the surface of the tissue. When spraying TISSEEL, changes in blood pressure, pulse, oxygen saturation and end tidal CO<sub>2</sub> should be monitored because of the possibility of occurrence of air or gas embolism. When using the EASYSpray device, or an equivalent spray device for open surgical procedures cleared by FDA, TISSEEL must not be sprayed in enclosed body areas and must be sprayed onto only visible application sites.

The sealer protein and thrombin solutions are denatured by alcohol, iodine or heavy metal ions. If any of these substances have been used to clean the wound area, the area must be thoroughly rinsed before the application of TISSEEL.

Apply TISSEEL as a thin layer as excess clot thickness may negatively interfere with wound healing.

#### 5.3 Use in Surgery

196 Caution should be exercised to minimize the risk of intravascular application when using TISSEEL in surgery (see *Contraindications (4.1) and Adverse*  
197 *Reactions (6.2)*).

#### 198 199 **5.4 Use in Neurosurgical Procedures**

200 The safety and effectiveness of TISSEEL used alone or in combination with biocompatible carriers in neurosurgical procedures or other surgeries  
201 involving confined spaces have not been evaluated, and its use in this setting is not approved by FDA (see *Adverse Reactions (6.2) and Drug*  
202 *Interactions (7)*).

#### 203 204 **5.5 Infection Risk from Human Plasma**

205 TISSEEL is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. The  
206 risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for  
207 the presence of certain virus infections, and by inactivating and removing certain viruses during the manufacturing process (see *Description (11.1)*).  
208 Despite these measures, such products can still potentially transmit disease. Because this product is made from human blood, it may carry a risk of  
209 transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging  
210 viruses and other pathogens. The measures taken are considered effective for inactivation/removal of lipid enveloped viruses such as HIV, HBV, and  
211 HCV, and for the non-lipid enveloped virus such as HAV. These measures may be of limited value against small non-lipid enveloped viruses such as  
212 Parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased  
213 red blood cell turnover (e.g., hemolytic anemia) (see *Patient Counseling Information (17)*). ALL infections thought by a physician possibly to have been  
214 transmitted by this product should be reported by the physician or other healthcare provider to Baxter Healthcare Corporation, telephone # 1-866-888-  
215 2472.

### 216 217 **6 ADVERSE REACTIONS**

218 Hypersensitivity or allergic/anaphylactoid reactions have occurred. In isolated cases, these reactions have progressed to severe anaphylaxis (see  
219 *Warnings and Precautions (5.1)*). No adverse events of this type were reported during clinical trials.

#### 220 221 **6.1 Clinical Trials Experience**

222 *Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly*  
223 *compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.*

224  
225 Increased D-Dimer levels have been observed during a clinical study in cardiovascular surgery (see *Clinical Studies (14)*), but did not exceed values  
226 reported in the literature occurring after this type of surgery. Postoperatively increased D-Dimers may result at least partly from the degradation of Fibrin  
227 Sealant.

228  
229 There were no reports of serious, associated adverse reactions reported above 1% in clinical studies.

#### 230 231 **6.2 Post-Marketing Experience**

232 *Because adverse reactions are reported voluntarily and the population is of uncertain size, it is not always possible to reliably estimate the frequency of*  
233 *these reactions.*

234  
235 The following adverse reactions have been reported in the post-marketing experience.

236  
237 **IMMUNE SYSTEM DISORDERS:** Hypersensitivity, including anaphylactic reactions and anaphylactic shock. Anaphylactic reactions and anaphylactic  
238 shock have included fatal outcomes.

239 **VASCULAR DISORDERS:** hypotension, thromboembolism, including cerebral artery embolism, cerebral infarction\*

240 **SKIN AND SUBCUTANEOUS TISSUE DISORDERS:** angioedema, erythema, impaired wound healing, pruritus, urticaria

241 **CARDIAC DISORDERS:** bradycardia, tachycardia

242 **RESPIRATORY DISORDERS:** bronchospasm, dyspnea, wheezing

243 **GASTROINTESTINAL DISORDERS:** nausea

244 **GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS:** flushing, paresthesia

245 \* as a result of intravascular application into the superior petrosal sinus

246  
247 **Class Effect:** Air embolism has occurred with misapplication of fibrin sealant using the spray device. A post marketing fatality was reported in  
248 association with the use of another fibrin sealant when applied using a spray device. The case involved an attempt to stop active bleeding by applying  
249 the fibrin sealant using a spray device attached to a wall unit at a higher than recommended pressure for the spray device. In addition, the spray head  
250 was placed at a distance from the bleeding site that was closer than the recommended distance guidelines for the application of the sealant. The patient  
251 suffered a fatal air embolism.

252  
253 Manifestations of hypersensitivity or allergic reactions associated with the class of fibrin sealant/hemostatic products include: application site irritation,  
254 chest discomfort, chills, headache, lethargy, restlessness and vomiting. There have been no reports of these reactions related to the specific use of  
255 TISSEEL

256  
257 There have been reports of serious adverse events such as paralysis and other compressive complications possibly related to the use of fibrin sealants  
258 in combination with resorbable hemostatic agents. There have also been reports of fatalities following the misadministration of topical thrombin (see  
259 *Warnings and Precautions (5.4)*).

### 260 261 **7 DRUG INTERACTIONS**

262 Oxidized cellulose-containing preparations may reduce the efficacy of TISSEEL and should not be used as carrier materials.

263 No interaction studies have been performed.

### 264 265 **8 USE IN SPECIFIC POPULATIONS**

#### 266 **8.1 Pregnancy**

##### 267 **Pregnancy Category C**

268 Animal reproduction studies have not been conducted with TISSEEL. It is also not known whether TISSEEL can cause fetal harm when administered to  
269 a pregnant woman or can affect reproduction capacity. Some viruses, such as parvovirus B19, are particularly difficult to remove or inactivate at this  
270 time. Parvovirus B19 most seriously affects pregnant women (fetal infection). TISSEEL should be given to a pregnant woman only if clearly needed.

271

272 **8.3 Nursing Mothers**

273 It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when  
274 TISSEEL is administered to nursing mothers.

275  
276 **8.4 Pediatric Use**

277 Limited clinical study data are available with regard to the use of TISSEEL in children. Of 365 patients undergoing repeated cardiac surgery or  
278 emergency re sternotomy in a clinical trial of TISSEEL, 27 pediatric patients aged 16 years or younger were treated with TISSEEL. Of these, 2 patients  
279 were less than 6 months, 2 patients were between the ages of 6 months and 2 years, 15 patients were between 3-11 years of age, and 8 patients were  
280 between 12-16 years of age. There were no differences in safety observed between these subjects and the overall population. (see *Clinical Studies*  
281 (14)).

282  
283 **8.5 Geriatric Use**

284 Clinical studies included 218 patients aged 65 years of age or older treated with TISSEEL (159 undergoing cardiac surgery and 59 undergoing vascular  
285 surgery) (see *Clinical Studies* (14)). No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and  
286 other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some  
287 older individuals cannot be ruled out.

288  
289 **11 DESCRIPTION**

290 TISSEEL [Fibrin Sealant] is a two-component fibrin sealant made from pooled human plasma. When combined, the two components, Sealer Protein and  
291 Thrombin mimic the final stage of the blood coagulation cascade.

292  
293 **Sealer Protein (Human)**

294 Sealer Protein (Human) is a sterile, non-pyrogenic, vapor heated and solvent/detergent treated preparation made from pooled human plasma. Sealer  
295 Protein (Human) is provided either as a freeze-dried powder for reconstitution with Fibrinolysis Inhibitor Solution or as a finished frozen solution pre-filled  
296 into one side of a dual-chambered syringe. The active ingredient in Sealer Protein (Human) is fibrinogen. Sealer Protein (Human) solution contains  
297 fibrinolysis inhibitor, synthetic Aprotinin, that delays fibrinolysis. Aprotinin (Synthetic) is manufactured by solid phase synthesis from materials  
298 completely of non-human/non-animal origin.

299  
300 **Thrombin (Human)**

301 Thrombin (Human) is a sterile, non-pyrogenic, vapor heated and solvent/detergent treated preparation made from pooled human plasma. Thrombin  
302 (Human) is also provided either as a freeze-dried powder for reconstitution with Calcium Chloride Solution or as a finished frozen solution pre-filled into  
303 one side of a dual-chambered syringe

304  
305 The reconstituted solution or pre-filled syringe contains:

306 **Sealer Protein Solution**

307 Total protein: 96 – 125 mg/mL  
308 Fibrinogen: 67 – 106 mg/mL  
309 Aprotinin (Synthetic): 2250 – 3750 KIU/mL  
310 Other ingredients include: human albumin, tri-sodium citrate, histidine, niacinamide, polysorbate 80 and water for injection.

311  
312 **Thrombin Solution**

313 Thrombin (Human): 400 – 625 units/mL\*  
314 Calcium Chloride: 36 – 44 µmol/mL  
315 Other ingredients include: human albumin, sodium chloride and water for injection.

316  
317 \* The potency expressed in units is determined with a clotting assay using an in-house internal standard that has been calibrated against the World  
318 Health Organization (WHO) Second International Standard for Thrombin, 01/580. Therefore, a unit (U) is equivalent to an International Unit (IU).

319  
320 **11.1 Viral Clearance**

321 TISSEEL is made from pooled human plasma collected at US licensed collection centers. The vapor heat and solvent/detergent treatment steps used in  
322 the manufacturing process have been shown to be capable of significant viral reduction. No procedure, however, has been shown to be completely  
323 effective in removing viral infectivity from derivatives of human plasma (see *Warnings and Precautions* (5.5)). Validation studies were conducted using  
324 samples drawn from manufacturing intermediates for each of the two human plasma derived components. These samples were spiked with stock virus  
325 suspensions of known titers followed by further processing under conditions representative of respective manufacturing steps.

326  
327 The virus reduction factors (expressed as log<sub>10</sub>) of manufacturing steps for each of the viruses tested are shown in Table 5.

328  
329 **Table 5: Reduction Factors for Virus Removal and/or Inactivation**

Sealer Protein Component					
Manufacturing Step	Mean Reduction Factors [log <sub>10</sub> ] of Virus Tested				
	HIV-1	HAV	BVDV	PRV	MMV
Early Manufacturing Steps	n.d.	n.d.	n.d.	n.d.	2.7
Solvent/Detergent Treatment	>5.3	n.d.	>5.7	>5.9	n.d.
Vapor Heat Treatment	>5.5	>5.6	>5.7	>6.7	1.2
Overall Reduction Factor (ORF)	>10.8	>5.6	>11.4	>12.6	3.9

Thrombin Component					
Manufacturing Step	Mean Reduction Factors [log <sub>10</sub> ] of Virus Tested				
	HIV-1	HAV	BVDV	PRV	MMV
Thrombin Precursor Mass Capture	3.2	1.5	1.8	2.5	1.2
Vapor Heat Treatment	>5.5	>4.9	>5.3	>6.7	1.0
Solvent/Detergent Treatment	>5.3	n.d.	>5.5	>6.4	n.d.
Ion Exchange Chromatography	n.d.	n.d.	n.d.	n.d.	3.6
Overall Reduction Factor (ORF)	>14.0	>6.4	>12.6	>15.6	5.8

330 n.d. = not determined

331

332 **HIV-1:** Human Immunodeficiency Virus 1; **HAV:** Hepatitis A Virus; **BVDV:** Bovine Viral Diarrhea Virus, a model for Hepatitis C Virus; **PRV:** Pseudorabies  
333 Virus, a model for lipid enveloped DNA viruses, among those is Hepatitis B Virus; **MMV:** Mouse Minute Virus, a model for B19V.

334

335 In addition, Human Parvovirus B19 (B19V) was used to investigate the upstream Thrombin precursor mass capture step, the Sealer Protein early  
336 manufacturing steps and the Thrombin and Sealer Protein vapor heating steps. Using quantitative PCR assays, the estimated B19V log reduction  
337 factors were: (a) 1.7 for the Thrombin precursor mass capture step, (b) 3.4 for Sealer Protein early manufacturing steps, (c) >4 for Thrombin vapor heat  
338 treatment and (d) 1.0 for Sealer Protein vapor heat treatment.

339

## 340 12 CLINICAL PHARMACOLOGY

### 341 12.1 Mechanism of Action

342 Upon mixing Sealer Protein (Human) and Thrombin (Human), soluble fibrinogen is transformed into fibrin, forming a rubber-like mass that adheres to the  
343 wound surface and achieves hemostasis and sealing or gluing of tissues. TISSEEL mimics the final coagulation cascade step as it has all relevant  
344 components to form a clot. TISSEEL is effective in heparinized patients and in patients medicated with anti-platelet drugs.

345

### 346 12.2 Pharmacodynamics

347 Thrombin is a highly specific protease that transforms the fibrinogen contained in Sealer Protein (Human) into fibrin. Fibrinolysis inhibitor, Aprotinin  
348 (Synthetic), is a polyvalent protease inhibitor that prevents premature degradation of fibrin. Preclinical studies with different fibrin sealant preparations  
349 simulating the fibrinolytic activity generated by extracorporeal circulation in patients during cardiovascular surgery have shown that incorporation of  
350 aprotinin in the product formulation increases resistance of the fibrin sealant clot to degradation in a fibrinolytic environment.

351

### 352 12.3 Pharmacokinetics

353 Unincorporated Aprotinin and its metabolites have a half-life of 30 to 60 minutes and are eliminated by the kidney. Pharmacokinetic studies were not  
354 conducted. TISSEEL is expected to be completely resorbed in 10 to 14 days

355

356 Because TISSEEL is applied only topically, systemic exposure or distribution to other organs or tissues is not expected.

357

## 358 13 NONCLINICAL TOXICOLOGY

### 359 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

360 Long-term animal studies to evaluate the carcinogenic potential of TISSEEL or studies to determine the effect of TISSEEL on fertility have not been  
361 performed.

362

## 363 14 CLINICAL STUDIES

### 364 14.1 Vascular Surgery

365 TISSEEL was evaluated in a prospective, controlled, randomized, single-blind, multicenter clinical study against manual compression with gauze pads in  
366 140 subjects undergoing vascular surgery with expanded polytetrafluoroethylene (ePTFE) graft placement (arterio-arterial bypasses and AV shunts for  
367 dialysis access in the upper and lower extremity). Subjects received standardized dosages of heparin. Protamine was administered after the primary  
368 endpoint had been assessed. Long-term antiplatelet treatments were continued perioperatively at the surgeon's discretion.

369

370 Subjects were randomly assigned to TISSEEL or control when persistent bleeding at the study suture line was present after surgical hemostasis, i.e.,  
371 sutures. Eligible bleedings before clamping and treatment application were defined as a minimum of 25% of the suture line bleeds or at least 5 suture  
372 line bleedings or any pulsatile or spurting needle hole bleeding. For the primary endpoint, hemostasis achieved at the study suture line at 4 minutes and  
373 maintained until surgical closure, a single application of TISSEEL was statistically significantly superior to control (p<0.0001; likelihood ratio chi-square  
374 test; 2.5% one sided) [ITT].

375

376

**Table 6: Vascular Surgery**

Hemostasis at the study suture line within 4 minutes and maintained until surgical closure		
	TISSEEL	Manual Compression
Intent to Treat Analysis	44/70 (62.9%)	22/70 (31.4%)

377

### 378 14.2 Cardiac Surgery

379 TISSEEL was evaluated in a prospective, parallel design, randomized (1:1), double-blind, multicenter clinical study against an earlier formulation of the  
380 product, TISSEEL VH, in 317 subjects undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) and median sternotomy. Patients were  
381 treated with TISSEEL or the control product only when hemostasis was not achieved by conventional surgical methods. For the endpoint, hemostasis

382 achieved at the primary treatment site within 5 minutes of treatment and maintained until closure of the surgical wound, TISSEEL was non-inferior to the  
 383 earlier formulation of the product using a one-sided 97.5% confidence interval on the difference in the proportion of subjects successfully treated.  
 384  
 385

**Table 7: Cardiac Surgery**

Hemostasis within 5 minutes and maintained until surgical closure		
	TISSEEL	TISSEEL VH
Intent to Treat Analysis	127/144 (88.2%)	129/144 (89.6%)

386  
 387 **14.3 Cardiac Reoperations**

388 An earlier formulation of TISSEEL was evaluated in an open-label crossover study against control topical hemostatic agents in 489 patients undergoing  
 389 cardiovascular reoperation or re-sternotomy at 11 institutions. Patients were randomized to TISSEEL or control hemostatic agents when a topical  
 390 hemostatic was needed at the conclusion of surgery and after all attempts at surgical hemostasis. Patients were crossed to the alternative therapy if  
 391 bleeding continued after the 5 minute endpoint. At 10 centers, TISSEEL was used after administration of protamine sulfate. At one site, TISSEEL could  
 392 be used before administration of protamine sulfate. 365 of the 489 patients developed bleeding episodes requiring treatment. For the endpoint  
 393 (successful hemostasis at 5 minutes), TISSEEL was statistically significantly superior to control topical hemostatic agents in these patients. Similarly,  
 394 absolute time to cessation of bleeding was statistically significantly shorter for TISSEEL than for control topical hemostatic agents (p<0.0001, Gehan-  
 395 Wilcoxon test, two sided).  
 396

**Table 8: Cardiac Reoperations**

Hemostasis within 5 minutes	
TISSEEL	Control Topical Hemostatic Agent
82.4% (159/193)	44.5% (76/172)
Pearson $\chi^2$ two sided; p <0.0001; intent-to-treat analysis	

397  
 398 **14.4 Splenectomy**

399 In a single center, open label trial, an earlier formulation of TISSEEL was compared to historical controls in patients undergoing laparotomy for blunt or  
 400 penetrating traumatic injury to the spleen and/or liver. Use of TISSEEL resulted in the need for statistically significantly fewer splenectomies than control  
 401 hemostatic maneuvers (Refer to Table 9). TISSEEL did not result in significantly reduced mortality in patients with blunt or penetrating trauma to the  
 402 liver alone or to the liver and spleen (p=0.067,  $\chi^2$ , one sided).  
 403

**Table 9: Splenectomy**

Splenectomy Rate			
Injury to:	TISSEEL	Historic Controls	
Spleen	0/19	14/22	p <0.001
Spleen and liver	1/26	19/34	p <0.001

404  
 405 **14.5 Colostomy Closure**

406 In a single center, prospective open label study of 118 patients randomized to standard of care (58 patients) or standard of care plus fibrin sealant (60  
 407 patients) for elective colostomy closure after temporary colostomy placement for treatment of traumatic injury to the colon, the earlier version of  
 408 TISSEEL plus standard of care was also shown to be significantly superior to standard of care alone (p=0.0406, Jonckheere-Terpstra test for ordinal  
 409 data, two sided) with regard to anastomotic complications (leakage, intra-abdominal abscess formation, re-operation, septic shock, and death).  
 410

411 **16 HOW SUPPLIED/STORAGE AND HANDLING**

412 **How Supplied**

413 TISSEEL is supplied in the following pack sizes and presentations:  
 414

**Table 10: NDC Numbers**

Pack Size	TISSEEL Kit (Freeze-Dried)	TISSEEL Kit (Freeze-Dried) with DUPLOJECT System	TISSEEL Pre-Filled Syringe (Frozen) with DUO Set
2 mL	0944-4201-03	0944-4201-04	0944-8402-02
4 mL	0944-4201-07	0944-4201-08	0944-8402-04
10 mL	0944-4201-11	0944-4201-12	0944-8402-10

415 TISSEEL Kit contains one vial each of:  
 416

- 417 1. Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, Freeze-Dried, Sterile
- 418 2. Fibrinolysis Inhibitor Solution, (Synthetic) Liquid, Sterile
- 419 3. Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, Freeze-Dried, Sterile
- 420 4. Calcium Chloride Solution, Liquid, Sterile

421 TISSEEL Pre-Filled Dual-Chambered Syringe contains:

- 422 1. Sealer Protein Solution, Vapor Heated, Solvent/Detergent Treated, Frozen Solution, Sterile
- 423 2. Thrombin Solution, Vapor Heated, Solvent/Detergent Treated, Frozen Solution, Sterile
- 424 3. Sterile accessory devices (DUO Set: 1 plunger, 2 joining pieces and 4 application cannulas)

425  
 426  
 427 **Storage**

428 **TISSEEL Kit (Freeze-Dried)**

429 Store at 2-25°C. Avoid freezing. Do not freeze or refrigerate reconstituted solutions.  
 430

431 **TISSEEL Pre-filled Syringe (Frozen)**

432 Store at ≤ -20°C. Do not refrigerate or re-freeze after thawing.  
 433

434 Do not use after the expiration date. Discard if packaging of any components is damaged.  
 435

436 **17 PATIENT COUNSELING INFORMATION**

437 Discuss the risks and benefits of this product with the patient since it is made from human plasma.  
 438

439 Instruct patients to consult their physician if symptoms of B19 virus infection appear (fever, drowsiness, chills and runny nose) followed about two weeks  
 440 later by a rash and joint pain (see *Use in Specific Populations* (8.1)).



441

442 **Baxter Healthcare Corporation**

443 Westlake Village, CA 91362 USA

444 US License No. 140

445

446 This product is covered by US Patent No. 5,962,405.

447 Baxter, Duo, Duploject, Easyspray, Fibrinotherm and Tisseel are trademarks of Baxter International Inc.

448

449